Safety and effectiveness of biphasic insulin aspart 30/70 (NovoMix 30
) when switching from human premix insulin in patients with type 2 diabetes: subgroup analysis from the 6-month IMPROVE observational study.
5 December 2011 - Danish pharma major Novo Nordisk A/S (CPH:NOVO B) announced today positive results with its insulin analogues NovoMix 30
, Levemir and NovoRapid, including better glucose control and improved rates of hypoglycaemia in patients with type 2 diabetes.
(11.) NovoMix 30
FlexPen prospektus bilgisi, Novo Nordisk Production SAS 45, Avenue d'Orleans, F-28002 Chartres, Fransa.
They were randomized to one of three regimens in the first year: prandial insulin aspart (NovoRapid) three times daily, biphasic insulin aspart (NovoMix 30
) twice daily, or basal detemir (Levemir) once or twice daily.
They were randomized to one of three supplemental insulin regimens in the first year: prandial insulin aspart (NovoRapid) three times daily, biphasic insulin aspart (NovoMix 30
) twice daily, or basal detemir (Levemir) once daily, or twice if needed.
Each patient took the biphasic insulin (marketed as NovoMix 30
) as directed by their clinician for 26 weeks, and their data was recorded at baseline, three months and at the final visit.
In this study, 708 adults with type 2 diabetes-and an Hb [A.sub.1c] level between 7% and 10% despite maximal therapy with metformin and a sulfonylurea--were randomized to 1 of 3 groups: (1) twice-daily biphasic insulin aspart 30 (NovoMix 30
); (2) 3-times-daily preprandial insulin aspart (NovoRapid); and (3) oncedaily basal insulin detemir at bedtime (Levemir).
Intensification to biphasic insulin aspart 30/70 (BIAsp 30, NovoMix 30
) can improve glycaemic control in patients treated with basal insulins: a subgroup analysis of the IMPROVE observational study.